Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Genetic variation of the gene coding for microRNA-204 (miR-204) is a risk factor in acute myeloid leukaemia.

Butrym A, Łacina P, Kuliczkowski K, Bogunia-Kubik K, Mazur G.

BMC Cancer. 2018 Jan 30;18(1):107. doi: 10.1186/s12885-018-4045-y.

2.

The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.

Díaz-Beyá M, Brunet S, Nomdedéu J, Pratcorona M, Cordeiro A, Gallardo D, Escoda L, Tormo M, Heras I, Ribera JM, Duarte R, de Llano MP, Bargay J, Sampol A, Nomdedeu M, Risueño RM, Hoyos M, Sierra J, Monzo M, Navarro A, Esteve J; Cooperative AML group CETLAM.

Oncotarget. 2015 Oct 13;6(31):31613-27. doi: 10.18632/oncotarget.5148.

3.

Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia.

Wang Z, Hong Z, Gao F, Feng W.

Mol Cell Biochem. 2013 Nov;383(1-2):59-65. doi: 10.1007/s11010-013-1754-z. Epub 2013 Jul 18.

PMID:
23864342
4.

MicroRNA-183 promotes cell proliferation via regulating programmed cell death 6 in pediatric acute myeloid leukemia.

Wang X, Zuo D, Yuan Y, Yang X, Hong Z, Zhang R.

J Cancer Res Clin Oncol. 2017 Jan;143(1):169-180. doi: 10.1007/s00432-016-2277-2. Epub 2016 Oct 13.

PMID:
27738758
5.

Serum MicroRNA-370 as a potential diagnostic and prognostic biomarker for pediatric acute myeloid leukemia.

Lin X, Wang Z, Wang Y, Feng W.

Int J Clin Exp Pathol. 2015 Nov 1;8(11):14658-66. eCollection 2015.

6.

Hypermethylation and down-regulation of DLEU2 in paediatric acute myeloid leukaemia independent of embedded tumour suppressor miR-15a/16-1.

Morenos L, Chatterton Z, Ng JL, Halemba MS, Parkinson-Bates M, Mechinaud F, Elwood N, Saffery R, Wong NC.

Mol Cancer. 2014 May 24;13:123. doi: 10.1186/1476-4598-13-123.

7.

De Novo Acute Myeloid Leukemia in Adults: Suppression of MicroRNA-223 is Independent of LMO2 Protein Expression BUT Associate With Adverse Cytogenetic Profile and Undifferentiated Blast Morphology.

Akhter A, Patel JL, Farooq F, Qureshi A, Taher-Rad MS, Elyamany G, Al-Zahrani AM, Rashid-Kolvear F, Mansoor A.

Appl Immunohistochem Mol Morphol. 2015 Nov-Dec;23(10):733-9. doi: 10.1097/PAI.0000000000000145.

PMID:
25710580
8.

MicroRNAs expression signatures are associated with lineage and survival in acute leukemias.

Wang Y, Li Z, He C, Wang D, Yuan X, Chen J, Jin J.

Blood Cells Mol Dis. 2010 Mar 15;44(3):191-7. doi: 10.1016/j.bcmd.2009.12.010. Epub 2010 Jan 27.

9.

Down-Regulation of miR-186 Correlates with Poor Survival in de novo Acute Myeloid Leukemia.

Zhang TJ, Wang YX, Yang DQ, Yao DM, Yang L, Zhou JD, Deng ZQ, Wen XM, Guo H, Ma JC, Lin J, Qian J.

Clin Lab. 2016;62(1-2):113-20.

PMID:
27012040
10.

Polymorphisms in microRNA target sites modulate risk of lymphoblastic and myeloid leukemias and affect microRNA binding.

Dzikiewicz-Krawczyk A, Macieja A, Mały E, Januszkiewicz-Lewandowska D, Mosor M, Fichna M, Strauss E, Nowak J.

J Hematol Oncol. 2014 Jun 2;7:43. doi: 10.1186/1756-8722-7-43.

11.

High bone marrow miR-19b level predicts poor prognosis and disease recurrence in de novo acute myeloid leukemia.

Zhang TJ, Lin J, Zhou JD, Li XX, Zhang W, Guo H, Xu ZJ, Yan Y, Ma JC, Qian J.

Gene. 2018 Jan 15;640:79-85. doi: 10.1016/j.gene.2017.10.034. Epub 2017 Oct 12.

PMID:
29032147
12.

The 5' flanking region of miR-378 is hypomethylated in acute myeloid leukemia.

Zhu XW, Wen XM, Zhang YY, Yang L, Guo H, Yang J, Zhang M, Yin JY, Ma JC, Lin J, Deng ZQ, Qian J.

Int J Clin Exp Pathol. 2015 May 1;8(5):4321-31. eCollection 2015.

13.

Prognostic value of miR-29a expression in pediatric acute myeloid leukemia.

Zhu C, Wang Y, Kuai W, Sun X, Chen H, Hong Z.

Clin Biochem. 2013 Jan;46(1-2):49-53. doi: 10.1016/j.clinbiochem.2012.09.002. Epub 2012 Sep 12.

PMID:
22981932
14.

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Marcucci G, Maharry K, Wu YZ, Radmacher MD, Mrózek K, Margeson D, Holland KB, Whitman SP, Becker H, Schwind S, Metzeler KH, Powell BL, Carter TH, Kolitz JE, Wetzler M, Carroll AJ, Baer MR, Caligiuri MA, Larson RA, Bloomfield CD.

J Clin Oncol. 2010 May 10;28(14):2348-55. doi: 10.1200/JCO.2009.27.3730. Epub 2010 Apr 5.

15.

Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.

Marcucci G, Maharry KS, Metzeler KH, Volinia S, Wu YZ, Mrózek K, Nicolet D, Kohlschmidt J, Whitman SP, Mendler JH, Schwind S, Becker H, Eisfeld AK, Carroll AJ, Powell BL, Kolitz JE, Garzon R, Caligiuri MA, Stone RM, Bloomfield CD.

J Clin Oncol. 2013 Jun 10;31(17):2086-93. doi: 10.1200/JCO.2012.45.6228. Epub 2013 May 6.

16.

TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.

Metzeler KH, Maharry K, Radmacher MD, Mrózek K, Margeson D, Becker H, Curfman J, Holland KB, Schwind S, Whitman SP, Wu YZ, Blum W, Powell BL, Carter TH, Wetzler M, Moore JO, Kolitz JE, Baer MR, Carroll AJ, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD.

J Clin Oncol. 2011 Apr 1;29(10):1373-81. doi: 10.1200/JCO.2010.32.7742. Epub 2011 Feb 22.

17.

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.

Díaz-Beyá M, Brunet S, Nomdedéu J, Cordeiro A, Tormo M, Escoda L, Ribera JM, Arnan M, Heras I, Gallardo D, Bargay J, Queipo de Llano MP, Salamero O, Martí JM, Sampol A, Pedro C, Hoyos M, Pratcorona M, Castellano JJ, Nomdedeu M, Risueño RM, Sierra J, Monzó M, Navarro A, Esteve J.

Blood Cancer J. 2015 Oct 2;5:e352. doi: 10.1038/bcj.2015.76.

18.

Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia.

Huang Y, Zou Y, Lin L, Ma X, Chen H.

Cancer Biomark. 2018;22(4):799-805. doi: 10.3233/CBM-181381.

PMID:
29945348
19.

Deregulation of miR-1, miR486, and let-7a in cytogenetically normal acute myeloid leukemia: association with NPM1 and FLT3 mutation and clinical characteristics.

Seyyedi SS, Soleimani M, Yaghmaie M, Ajami M, Ajami M, Pourbeyranvand S, Alimoghaddam K, Akrami SM.

Tumour Biol. 2016 Apr;37(4):4841-7. doi: 10.1007/s13277-015-4289-y. Epub 2015 Nov 2.

PMID:
26526573
20.

Low expression of circulating microRNA-328 is associated with poor prognosis in patients with acute myeloid leukemia.

Liu L, Chen R, Zhang Y, Fan W, Xiao F, Yan X.

Diagn Pathol. 2015 Jul 17;10:109. doi: 10.1186/s13000-015-0345-6.

Supplemental Content

Support Center